Urinary Tract Infections (UTI)

FDA Panel Votes on Novel Antibiotic for Complicated UTI

Publish Date October 18, 2019

The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.

Comparison of Antibiotic Activity in Complicated UTI From Gram-Negative Bacteria

Publish Date October 17, 2019

Ceftazidime-avibactam was highly active against a large collection of gram-negative bacteria isolated from patients with complicated urinary tract infections.

Urinary Catheters Not Needed for Joint Replacement Surgery

Publish Date October 2, 2019

There is no increased risk for adverse genitourinary complications without the catheter

USPSTF Urges Asymptomatic Bacteriuria Screening in Pregnancy

Publish Date September 24, 2019

No net benefit seen for screening, treatment of asymptomatic bacteriuria for nonpregnant adults

Aortic, Mitral Regurgitation Risk Up With Fluoroquinolone Use

Publish Date September 18, 2019

Risk significantly increased for current use and recent use, but not past use within 61 to 365 days

Most UK Patients With UTI Receive Antibiotics on Same Day

Publish Date August 20, 2019

Represcription rate at 28 days only 4.1% from 2011 to 2015; slight increase seen for men over time

Renal Anomaly on Fetal Scan May Up Risk for Admission for Child

Publish Date August 15, 2019

Renal pelvis dilatation persisting in later pregnancy or after birth tied to increased risk for later admission

Recurrent Febrile UTI in Children Raises Renal Scarring Risk

Publish Date August 23, 2019

Children who have a second febrile UTI had a nearly 12 times higher risk of renal scarring than those who have a single febrile UTI, according to investigators.

SGLT-2 Inhibitors Do Not Increase Risk for UTI in Type 2 Diabetes

Publish Date July 31, 2019

Study finds no increased risks for severe or nonsevere urinary tract infections with SGLT-2 inhibitor use compared with other second-line antidiabetic drugs in type 2 diabetes patients.

FDA Approves Recarbrio for Complicated UTI, Abdominal Infections

Publish Date July 17, 2019

The antibiotic Recarbrio is a combination of imipenem-cilastatin and relebactam.